Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06644781 · ClinicalTrials.gov registry record · Phase 3
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
A Phase 3 study of Esophageal Squamous Cell Carcinoma, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
- 20
- Study locations
NCT06644781 is a Phase 3 study of Esophageal Squamous Cell Carcinoma that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 510 participants, above the 357-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT06644781, a Phase 3 study of Esophageal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator's choice of chemotherapy (ICC).
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Ifinatamab deruxtecan
- DRUG Irinotecan hydrochloride (HCl)
Study Locations (20)
Other
- Institut Jules Bordet - Brussels
- Cliniques Universitaires Saint-Luc - Brussels
- Antwerp University Hospital - Edegem
- UZ Leuven - Leuven
- Anyang Cancer Hospital - Anyang
- Beijing Cancer Hospital - Beijing
- Jilin Cancer Hospital - Changchun
- Changzhou Cancer Hospital - Changzhou
- Sichuan cancer hospital - Chengdu
- West China Hospital Sichuan University - Chengdu
- Fujian Cancer Hospital - Fuzhou
- Harbin Medical University Cancer Hospital - Harbin
- The First Affiliated Hospital of Fujian Medical University - Hefei
- Jinan Central Hospital - Jinan
Tennessee
- Baptist Cancer Center - Memphis
- SCRI Oncology Partners - Nashville
California
- Providence Medical Foundation - Fullerton
Michigan
- Henry Ford Health System - Detroit
Texas
- John Peter Smith Hospital - Fort Worth
Virginia
- Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2029-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06644781
The ClinicalTrials.gov registry entry for NCT06644781 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 357-participant average among 22 other Esophageal Squamous Cell Carcinoma trials with a reported enrollment target (43% higher). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophageal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Docetaxel is the first listed.
NCT06644781 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, Tennessee, California.
Frequently Asked Questions
What is clinical trial NCT06644781 about?
NCT06644781 is a clinical study titled "A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)". This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune c...
What is the current status of trial NCT06644781?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2025-03-27. Estimated completion is 2029-11-01.
What conditions does trial NCT06644781 study?
This clinical trial studies the following conditions: Esophageal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06644781?
The interventions under investigation include: Docetaxel (DRUG), Paclitaxel (DRUG), Ifinatamab deruxtecan (DRUG), Irinotecan hydrochloride (HCl) (DRUG).
Who is sponsoring clinical trial NCT06644781?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06644781 being conducted?
This trial has 20 study locations across California, Michigan, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
ACTIVE NOT RECRUITING · Phase 3
-
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
COMPLETED · Phase 3
-
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
RECRUITING · Phase 1
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.